You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 25, 2025

CLINICAL TRIALS PROFILE FOR AURANOFIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Auranofin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00246064 ↗ The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol Completed Centocor Ortho Biotech Services, L.L.C. Phase 4 2001-12-01 The purpose of the study was to evaluate the ability of a maintenance dosage regimen of infliximab to achieve and sustain at least 40% improvement from baseline in the total joint count in patients with active Rheumatoid Arthritis (RA) during methotrexate tapering.
NCT01419691 ↗ Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) Completed Kansas Bioscience Authority Phase 2 2011-09-01 The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL).
NCT01419691 ↗ Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) Completed The Leukemia and Lymphoma Society Phase 2 2011-09-01 The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL).
NCT01419691 ↗ Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) Completed Therapeutics for Rare and Neglected Diseases (TRND) Phase 2 2011-09-01 The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL).
NCT01419691 ↗ Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) Completed University of Kansas Medical Center Phase 2 2011-09-01 The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL).
NCT01737502 ↗ Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer Recruiting National Cancer Institute (NCI) Phase 1/Phase 2 2012-11-29 This phase I/II trial studies the side effects and best dose of auranofin when given together with sirolimus and to see how well it works in treating patients with lung cancer that has spread or other places in the body and cannot be cured or controlled by treatment or has come back after a period of time during which the cancer could not be detected. Auranofin and sirolimus may stop or slow the growth of lung cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Auranofin

Condition Name

Condition Name for Auranofin
Intervention Trials
HIV 2
Amoebic Dysentery 1
Pain 1
Stage IIIB Non-Small Cell Lung Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Auranofin
Intervention Trials
Dysentery, Amebic 2
Lung Neoplasms 2
Amebiasis 2
Carcinoma, Non-Small-Cell Lung 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Auranofin

Trials by Country

Trials by Country for Auranofin
Location Trials
United States 9
South Africa 1
Brazil 1
Germany 1
Bangladesh 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Auranofin
Location Trials
Minnesota 3
Florida 3
Kansas 2
Arizona 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Auranofin

Clinical Trial Phase

Clinical Trial Phase for Auranofin
Clinical Trial Phase Trials
Phase 4 1
Phase 2 5
Phase 1/Phase 2 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Auranofin
Clinical Trial Phase Trials
Completed 7
Recruiting 2
Withdrawn 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Auranofin

Sponsor Name

Sponsor Name for Auranofin
Sponsor Trials
Mayo Clinic 5
National Cancer Institute (NCI) 4
National Institute of Allergy and Infectious Diseases (NIAID) 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Auranofin
Sponsor Trials
Other 16
NIH 7
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Auranofin: Clinical Trials, Market Analysis, and Projections

Introduction

Auranofin, a gold-based compound, has been a subject of significant interest in the medical and pharmaceutical industries due to its diverse therapeutic potential. Initially developed as an anti-rheumatic agent, auranofin is now being explored for its antiviral, antiparasitic, and anticancer properties. Here, we delve into the current state of clinical trials, market analysis, and future projections for auranofin.

Clinical Trials Update

Antiviral Properties

Auranofin is currently in several Phase II clinical trials for its antiviral properties, particularly against SARS-CoV-2. These trials aim to evaluate its efficacy in reducing the severity of COVID-19 by mitigating the cytokine storm, especially the expression of IL-6, which is a key factor in the severity of the disease[1].

Antiparasitic Properties

Clinical trials have also been conducted to assess auranofin's antiparasitic efficacy. A Phase I trial sponsored by the NIH has shown promising results in treating infections caused by Entamoeba histolytica and Giardia species. The trial demonstrated the safety and pharmacokinetics of auranofin, with mild and transient adverse events reported by 47% of the subjects[4].

Oncological Applications

Auranofin has been approved for clinical trials up to 21 mg/day for the treatment of relapsed chronic lymphocytic leukemia. These trials indicate that higher doses of auranofin can be well-tolerated, suggesting potential for its use in oncology[4].

Market Analysis

Current Market Size and Growth

The auranofin market was valued at USD 209.20 million in 2023 and is expected to reach USD 218.99 million in 2024. It is projected to grow at a Compound Annual Growth Rate (CAGR) of 4.81%, reaching USD 290.85 million by 2030[2][5].

Market Drivers

Key factors driving the growth of the auranofin market include:

  • Increasing Research Funding: Growing investment in research for autoimmune and inflammatory diseases.
  • Rising Incidence of Autoimmune Diseases: The increasing prevalence of conditions such as rheumatoid arthritis and other autoimmune diseases.
  • Demand for Targeted Therapies: The ongoing need for more effective and targeted treatments for various diseases[2][5].

Market Restraints

Despite the promising growth, several factors could limit the market expansion:

  • Potential Side Effects: Safety concerns and potential adverse effects, such as diarrhea, skin rashes, and hematologic abnormalities.
  • Regulatory and Environmental Challenges: Stringent regulatory paths and challenges in aligning auranofin formulation with modern environmental and sustainability standards[2][5].

Market Opportunities

Combination Therapies

There is significant potential in developing auranofin-based combination therapies for chronic diseases. This could unlock new market avenues and enhance the therapeutic profile of auranofin[2].

Niche Markets

Exploring niche markets in regions with high prevalence of specific infectious diseases could provide additional growth opportunities for auranofin[2].

Dermatological Applications

Investigating potential uses for auranofin in dermatological markets, given the rising skin health concerns, is another area of opportunity[2].

Competitive Landscape

Porter's Five Forces

The competitive landscape of the auranofin market can be analyzed using Porter's Five Forces framework. This tool helps businesses evaluate the power dynamics within the market, assess the profitability of new ventures, and determine their competitive positioning. It includes analyzing the threat of new entrants, the bargaining power of suppliers and buyers, the threat of substitute products, and the intensity of rivalry among competitors[5].

Product Development and Innovation

Recent Advances

Recent product launches and ongoing research and development efforts are crucial for the growth of the auranofin market. Advances in precision medicine and the exploration of auranofin in new therapeutic areas, such as cancer and neurodegenerative diseases, are expected to drive innovation and market expansion[2][5].

Cost Effectiveness

Studies have shown that auranofin can be cost-effective in treating conditions like rheumatoid arthritis. A randomized clinical trial demonstrated that the benefits of disease modification with auranofin outweigh the adverse effects and additional medical costs associated with the treatment[3].

Key Takeaways

  • Auranofin is being explored in various clinical trials for its antiviral, antiparasitic, and anticancer properties.
  • The market for auranofin is projected to grow at a CAGR of 4.81% from 2023 to 2030.
  • Key drivers include increasing research funding, rising incidence of autoimmune diseases, and demand for targeted therapies.
  • Potential side effects, regulatory challenges, and environmental concerns are significant restraints.
  • Opportunities exist in developing combination therapies, targeting niche markets, and exploring dermatological applications.

FAQs

What is the current status of auranofin in clinical trials?

Auranofin is currently in several Phase II clinical trials for its antiviral properties against SARS-CoV-2 and has shown promising results in Phase I trials for antiparasitic and oncological applications.

What is the projected market size of auranofin by 2030?

The auranofin market is projected to reach USD 290.85 million by 2030, growing at a CAGR of 4.81% from 2023.

What are the main drivers of the auranofin market growth?

The main drivers include increasing research funding for autoimmune and inflammatory diseases, the rising incidence of these conditions, and the ongoing demand for more effective, targeted therapies.

What are the potential side effects of auranofin?

Common side effects include diarrhea, skin rashes, hematologic abnormalities, and proteinuria, although these are generally mild and transient.

How does auranofin compare in terms of cost effectiveness?

Auranofin has been shown to be cost-effective in treating rheumatoid arthritis, with the benefits of disease modification outweighing the additional medical costs associated with the treatment.

Sources

  1. Frontiers in Immunology: "Will Auranofin Become a Golden New Treatment Against COVID-19?"[1]
  2. 360iResearch: "Auranofin Market Size & Share 2025-2030"[2]
  3. PubMed: "The cost effectiveness of auranofin: results of a randomized clinical trial"[3]
  4. ASM Journals: "Phase I Clinical Trial Results of Auranofin, a Novel Antiparasitic Agent"[4]
  5. GII Research: "Auranofin Market by Form, Indication - Global Forecast 2025-2030"[5]

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.